Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Egetis Therapeutics

11.20 SEK+0.72 %13/11 17:29
Less than 1K followers

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+0.72 %
+16.67 %
+54.70 %
+65.93 %
+109.74 %
+81.23 %
+119.18 %
+98.48 %
-19.06 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Read more
Market cap
5.5B SEK
Turnover
24.95M SEK
Revenue
62.4M
EBIT %
-544.71 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25/2
2027

Annual report '26

29/4
2027

Interim report Q1'27

20/8
2027

Interim report Q2'27

Regulatory press release2026-11-11 15:15

Finansinspektionen: Flaggningsmeddelande i Egetis Therapeutics AB (publ)

Egetis Therapeutics
Regulatory press release2026-11-05 07:30

Kvartalsrapport Q3 2026

Egetis Therapeutics
Regulatory press release2026-11-05 07:30

Interim report Q3 2026

Egetis Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-11-05 07:15

Uttalande från Egetis Therapeutics styrelse med anledning av ANI Pharmaceuticals kontanta offentliga uppköpserbjudande

Egetis Therapeutics
Regulatory press release2026-11-05 07:15

Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals

Egetis Therapeutics
Regulatory press release2026-11-04 08:32

Egetis Therapeutics ingår avtal om försäljning av Priority Review Voucher för 190 miljoner USD

Egetis Therapeutics
Regulatory press release2026-11-04 08:32

Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million

Egetis Therapeutics
Press release2026-10-27 14:00

Egetis Therapeutics påbörjar lanseringen av EMCITATE® i USA för patienter med MCT8-brist

Egetis Therapeutics
Press release2026-10-27 14:00

Egetis Therapeutics Announces U.S. Launch of EMCITATE® for Patients with MCT8 Deficiency

Egetis Therapeutics
Press release2026-10-21 18:00

Egetis valberedning utsedd inför årsstämman 2027

Egetis Therapeutics
Press release2026-10-21 18:00

Egetis’ Nomination Committee for the 2027 Annual General Meeting

Egetis Therapeutics
Press release2026-10-21 08:20

Analyst Group: Analyst Group intervjuar Egetis Therapeutics VD Nicklas Westerholm

Egetis Therapeutics
Press release2026-10-16 15:08

International retrospective cohort study published on "molecular mechanisms underlying the effectiveness of tiratricol in patients with resistance to thyroid hormone beta (RTH-beta)"

Egetis Therapeutics
Press release2026-10-16 15:08

Internationell retrospektiv kohortstudie publicerad om "de molekylära mekanismer som ligger bakom tiratricols effekt hos patienter med resistens mot sköldkörtelhormon beta (RTH-beta)"

Egetis Therapeutics
Regulatory press release2026-10-01 15:22

Finansinspektionen: Flaggningsmeddelande i Egetis Therapeutics AB (publ)

Egetis Therapeutics
Regulatory press release2026-10-01 14:23

Finansinspektionen: Flaggningsmeddelande i Egetis Therapeutics AB (publ)

Egetis Therapeutics
Regulatory press release2026-09-30 18:00

Förändring av antal aktier och röster i Egetis Therapeutics

Egetis Therapeutics
Regulatory press release2026-09-30 18:00

Changes in number of shares and votes in Egetis Therapeutics

Egetis Therapeutics
Egetis, FDA Approval
Webcast2026-09-29 08:00

Egetis, FDA Approval

Egetis Therapeutics
Regulatory press release2026-09-28 23:45

Egetis Therapeutics meddelar att amerikanska FDA har godkänt EMCITATE® (tiratricol) för patienter med MCT8-brist

Egetis Therapeutics